Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.53 |
| ▸ | UMPS | P11172 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 14/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 10/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiazofurin SCHEMBL1651851 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL4287 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL7169632 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL4453888 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL23848843 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL2883659 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL23264566 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL13109276 | 1.00 | PYGL (0.53) | PYGLUMPSIMPDH2IMPDH1 | |
| SCHEMBL7832887 | 0.89 | PYGL (0.53) | PYGLUMPS | |
| SCHEMBL23375983 | 0.88 | PYGL (0.43) | PYGLIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0707479-A4 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0707479-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1994026281-A1 | METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASE UTILIZING TIAZOFURIN AND RIBAVIRIN | INDIANA UNIVERSITY FOUNDATION (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0054432-A1 | Use of 2-Beta-D-ribofuranosylthiazole-4-carboxamides for the manufacture of medicaments inhibiting malignant tumors | VIRATEK, INC. (US) | 1982-06-23 | — | — | EP | claimed |
| US-10472677-B2 | Translational dysfunction based therapeutics | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-9365604-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-12-18 | — | — | US | disclosed |
| US-8741858-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS | 2014-06-03 | — | — | US | disclosed |
| US-20130253039-A1 | COLORECTAL CANCER TREATMENTS AND DIAGNOSTIC IMPROVEMENTS | JAYARAM HIREMAGALUR N (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013130672-A2 | IMPROVED CANCER TREATMENTS AND DIAGNOSTICS | UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009042064-A2 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-1154787-A2 | SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES | Institute of Molecular and Cell Biology (SG) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050064-A2 | SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES | INSTITUTE OF MOLECULAR AND CELL BIOLOGY (SG) | 2000-08-31 | — | — | WO | disclosed |
| US-4680285-A | Treatment of malignant tumors with 2-(β-D-ribofuranosylthiazole-4-carboxamide related compounds | VIRATEK, INC. (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0054432-A1 | Use of 2-Beta-D-ribofuranosylthiazole-4-carboxamides for the manufacture of medicaments inhibiting malignant tumors | VIRATEK, INC. (US) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | ENTPD5, SLC29A2, SLC29A1 | PYGL 432/4885UMPS 54/4885IMPDH2 357/4885 |
| US-10472677-B2 | Translational dysfunction based therapeutics | EIF4EBP1, EIF4E, EIF4A1 | PYGL 2504/4885UMPS 1957/4885IMPDH2 2652/4885 |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | ENTPD5, SLC29A2, SLC29A1 | PYGL 386/4885UMPS 58/4885IMPDH2 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.